--- title: "Edesa Biotech, Inc. SEC 10-Q Report" type: "News" locale: "en" url: "https://longbridge.com/en/news/275948505.md" description: "Edesa Biotech, Inc. has released its Form 10-Q report for Q3, revealing a net loss of $2.2 million, up from $1.6 million last year. Loss per share decreased to $0.28 from $0.48, attributed to a higher number of shares. The company is advancing its EB06 monoclonal antibody for vitiligo, with a Phase 2 study expected to start by mid-2026, and EB05 for ARDS, showing significant Phase 3 results. Edesa is focusing on strategic partnerships and regulatory approvals to support its clinical programs, while acknowledging the need for additional funding to continue operations." datetime: "2026-02-13T21:51:01.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/275948505.md) - [en](https://longbridge.com/en/news/275948505.md) - [zh-HK](https://longbridge.com/zh-HK/news/275948505.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/275948505.md) | [繁體中文](https://longbridge.com/zh-HK/news/275948505.md) # Edesa Biotech, Inc. SEC 10-Q Report Edesa Biotech, Inc., a biopharmaceutical company focused on acquiring, developing, and commercializing drugs for inflammatory and immune-related diseases, has released its Form 10-Q report for the third quarter. The report provides a comprehensive overview of the company's financial performance and operational advancements, underscoring its commitment to addressing unmet medical needs and exploring large market opportunities. **Financial Highlights** **Net Loss:** $2.2 million, reflecting an increase from the previous year's net loss of $1.6 million, primarily due to higher operating expenses. **Loss per Common Share - Basic and Diluted:** $0.28, compared to $0.48 for the same period last year, indicating a decrease in loss per share despite the increased net loss, likely due to a higher number of shares outstanding. **Business Highlights** **Product Development - Medical Dermatology** Edesa Biotech is advancing its EB06 monoclonal antibody candidate for vitiligo, with regulatory approval from Health Canada for a Phase 2 study and ongoing discussions with the FDA. The company plans to initiate enrollment by mid-2026. **Product Development - Respiratory** The company's most advanced candidate, EB05 (paridiprubart), showed significant results in a Phase 3 study for ARDS. It is also part of a U.S. government-funded study for ARDS and is being explored for chronic disease applications. **Operational Strategy** Edesa Biotech focuses on acquiring, developing, and commercializing drugs for inflammatory and immune-related diseases, prioritizing areas with unmet medical needs and large market opportunities. **Future Outlook - Clinical Trials** The company anticipates starting a Phase 2 study for EB06 in vitiligo patients by mid-2026, subject to regulatory approval, and is evaluating additional uses for EB05 in chronic diseases. **Strategic Partnerships** Edesa Biotech is leveraging government grants, such as the Canadian SRF, to support its clinical programs, including the development and potential commercialization of EB05. **Regulatory Progress** The company has received regulatory approval from Health Canada for a Phase 2 study of EB06 and is in discussions with the FDA for the same study, indicating progress in its regulatory strategy. **Research and Development Focus** Edesa Biotech's R&D efforts are concentrated on advancing its clinical pipeline in Medical Dermatology and Respiratory, with a focus on EB06 for vitiligo and EB05 for ARDS. **Operational Challenges** The company acknowledges the need for additional funding to continue its operations and advance its clinical programs, highlighting the importance of strategic financing and partnerships. SEC Filing: Edesa Biotech, Inc. \[ EDSA \] - 10-Q - Feb. 13, 2026 ### Related Stocks - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [Edesa Biotech, Inc. (EDSA.US)](https://longbridge.com/en/quote/EDSA.US.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) ## Related News & Research - [Opus Genetics Announces Initial Clinical Data from Phase 1/2 OPGx-BEST1 Gene Therapy Study at the Macula Society Annual Meeting | IRD Stock News](https://longbridge.com/en/news/277220357.md) - [Bioventus beats Q4 revenue estimates on strong demand for pain treatments and surgical solutions](https://longbridge.com/en/news/277932436.md) - [Anavex Life Sciences Touts Oral Alzheimer’s Drug Blarcamesine Data, Cash Runway at Healthcare Conference](https://longbridge.com/en/news/277943726.md) - [Lexaria Launches 2026 R&D Push to Advance GLP-1 and Cannabidiol Drug Delivery](https://longbridge.com/en/news/277804860.md) - [FDA official says UniQure fell short on Huntington's trial, defends new study request](https://longbridge.com/en/news/277874344.md)